These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37170951)

  • 21. Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis.
    Gooderham M; Pinter A; Ferris LK; Warren RB; Zhan T; Zeng J; Soliman AM; Kaufmann C; Kaplan B; Photowala H; Strober B
    J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):855-865. PubMed ID: 35174556
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis.
    Li W; Ghamrawi R; Haidari W; Feldman SR
    Ann Pharmacother; 2020 Apr; 54(4):380-387. PubMed ID: 31672037
    [No Abstract]   [Full Text] [Related]  

  • 23. Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
    Blauvelt A; Leonardi CL; Gooderham M; Papp KA; Philipp S; Wu JJ; Igarashi A; Flack M; Geng Z; Wu T; Camez A; Williams D; Langley RG
    JAMA Dermatol; 2020 Jun; 156(6):649-658. PubMed ID: 32267471
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis.
    Gordon KB; Lebwohl M; Papp KA; Bachelez H; Wu JJ; Langley RG; Blauvelt A; Kaplan B; Shah M; Zhao Y; Sinvhal R; Reich K
    Br J Dermatol; 2022 Mar; 186(3):466-475. PubMed ID: 34652810
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exposure-Response Relationships for Efficacy and Safety of Risankizumab in Phase II and III Trials in Psoriasis Patients.
    Khatri A; Suleiman AA; Polepally AR; Othman AA
    Clin Pharmacol Ther; 2020 Feb; 107(2):378-387. PubMed ID: 31355921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection.
    Megna M; Patruno C; Bongiorno MR; Gambardella A; Guarneri C; Romita P; Raimondo A; Loconsole F; Fabbrocini G
    Clin Drug Investig; 2022 Jun; 42(6):525-531. PubMed ID: 35633470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients.
    Pang Y; Khatri A; Suleiman AA; Othman AA
    Clin Pharmacokinet; 2020 Mar; 59(3):311-326. PubMed ID: 31758502
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Direct comparison of risankizumab and fumaric acid esters in systemic therapy-naïve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial.
    Thaçi D; Eyerich K; Pinter A; Sebastian M; Unnebrink K; Rubant S; Williams DA; Weisenseel P
    Br J Dermatol; 2022 Jan; 186(1):30-39. PubMed ID: 33991341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risankizumab in moderate-to-severe plaque psoriasis.
    Serrano L; Maloney V; Gordon KB
    Immunotherapy; 2019 Nov; 11(16):1357-1370. PubMed ID: 31578912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety of secukinumab in hepatitis B virus.
    Bevans SL; Mayo TT; Elewski BE
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):e120-e121. PubMed ID: 28960490
    [No Abstract]   [Full Text] [Related]  

  • 31. Effectiveness and safety of reduced-dose secukinumab switching to risankizumab for psoriasis patients in Asian population: A case series.
    Hsieh CY; Tsai TF
    Exp Dermatol; 2023 Jul; 32(7):1048-1050. PubMed ID: 37032610
    [No Abstract]   [Full Text] [Related]  

  • 32. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis.
    Fioranelli M; Roccia MG; Lotti T
    Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28508536
    [No Abstract]   [Full Text] [Related]  

  • 33. Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal.
    Al-Janabi A; Jabbar-Lopez ZK; Griffiths CEM; Yiu ZZN
    Br J Dermatol; 2019 Jun; 180(6):1348-1351. PubMed ID: 30632140
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis.
    Blauvelt A; Gordon KB; Lee P; Bagel J; Sofen H; Lockshin B; Soliman AM; Geng Z; Zhan T; Alperovich G; Stein Gold L
    J Dermatolog Treat; 2022 Jun; 33(4):2085-2093. PubMed ID: 33947295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study.
    Torres T; Puig L; Vender R; Yeung J; Carrascosa JM; Piaserico S; Gisondi P; Lynde C; Ferreira P; Bastos PM; Dauden E; Leite L; Valerio J; Del Alcázar-Viladomiu E; Rull EV; Llamas-Velasco M; Pirro F; Messina F; Bruni M; Licata G; Ricceri F; Nidegger A; Hugo J; Mufti A; Daponte AI; Teixeira L; Balato A; Romanelli M; Prignano F; Gkalpakiotis S; Conrad C; Lazaridou E; Rompoti N; Papoutsaki M; Nogueira M; Chiricozzi A
    Am J Clin Dermatol; 2022 Nov; 23(6):891-904. PubMed ID: 35976568
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risankizumab-induced paradoxical pustular psoriasis.
    McFeely O; Pender E; Victory L; Almutlaq H; Storan E
    Clin Exp Dermatol; 2022 Mar; 47(3):616-617. PubMed ID: 34748673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
    Papp KA; Blauvelt A; Bukhalo M; Gooderham M; Krueger JG; Lacour JP; Menter A; Philipp S; Sofen H; Tyring S; Berner BR; Visvanathan S; Pamulapati C; Bennett N; Flack M; Scholl P; Padula SJ
    N Engl J Med; 2017 Apr; 376(16):1551-1560. PubMed ID: 28423301
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.
    Reich K; Gooderham M; Thaçi D; Crowley JJ; Ryan C; Krueger JG; Tsai TF; Flack M; Gu Y; Williams DA; Thompson EHZ; Paul C
    Lancet; 2019 Aug; 394(10198):576-586. PubMed ID: 31280967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature.
    Piaserico S; Dapavo P; Conti A; Gisondi P; Russo FP
    J Eur Acad Dermatol Venereol; 2017 Nov; 31(11):1853-1859. PubMed ID: 28146345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of guselkumab in two psoriatic patients with hepatitis B and C virus infection.
    Messina F; Peccerillo F; Odorici G; Conti A; Piaserico S
    Dermatol Ther; 2022 Mar; 35(3):e15281. PubMed ID: 34931414
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.